Literature DB >> 19132151

[Hypocomplementemia in systemic sclerosis].

G Cuomo1, G Abignano, L Ruocco, S Vettori, G Valentini.   

Abstract

BACKGROUND: Hypocomplementemia has been detected in about 15% of unselected series of SSc patients. It constitutes one of the 10 parameters needed to evaluate the European Scleroderma Study Group (EScSG) activity index. A few studies have been so far devoted to investigate the clinical manifestations correlated with this finding.
OBJECTIVE: To investigate SSc patients for hypocomplementemia and point out clinical manifestations associated with it.
METHODS: 302 patients with SSc consecutively admitted to the Rheumatology Unit of the Second University of Naples were enrolled in the study. SSc patients were all investigated for sex, age, disease duration, clinical and serological subset, disease activity, organ/system severity and functional status. Patients were divided into 2 groups: normo-complementemic and hypocomplementemic (low C3 and/or C4) as measured by nephelometry.
RESULTS: 252 of the 302 patients had normal complementemia; 50 (16,5%) had hypocomplementemia. Significant associations were found between hypocomplementemia and EScSG activity index (p<0.0003); functional disability (i.e. HAQ-DI >0.5)( p=0.04); and the severity of general manifestations (p<0.006); skin (p<0.0001); vascular (p<0.0001); heart (p<0.0001) and lung (p<0.0001) involvement.
CONCLUSIONS: Our study confirms that hypocomplementemia occurs in patients with SSc. It resulted to be associated with disease activity, functional status and the severity of distinct disease manifestations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19132151     DOI: 10.4081/reumatismo.2008.268

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  4 in total

1.  The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study.

Authors:  Cinzia Scambi; Sara Ugolini; T Sakari Jokiranta; Lucia De Franceschi; Oscar Bortolami; Valentina La Verde; Patrizia Guarini; Paola Caramaschi; Viviana Ravagnani; Guido Martignoni; Chiara Colato; Serena Pedron; Fabio Benedetti; Marco Sorio; Fabio Poli; Domenico Biasi
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

2.  The association of low complement with disease activity in systemic sclerosis: a prospective cohort study.

Authors:  James Esposito; Zoe Brown; Wendy Stevens; Joanne Sahhar; Candice Rabusa; Jane Zochling; Janet Roddy; Jennifer Walker; Susanna M Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2016-10-22       Impact factor: 5.156

3.  Complement activation and effect of eculizumab in scleroderma renal crisis.

Authors:  Arnaud Devresse; Selda Aydin; Moglie Le Quintrec; Nathalie Demoulin; Patrick Stordeur; Catherine Lambert; Sara Gastoldi; Yves Pirson; Michel Jadoul; Johann Morelle
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 4.  Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases.

Authors:  Silvia Cavalli; Paola Adele Lonati; Maria Gerosa; Roberto Caporali; Rolando Cimaz; Cecilia Beatrice Chighizola
Journal:  Front Pharmacol       Date:  2022-02-15       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.